10x Genomics (NASDAQ:TXG) Shares Acquired by Diversified Trust Co

Diversified Trust Co lifted its stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 60.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 57,236 shares of the company's stock after purchasing an additional 21,634 shares during the quarter. Diversified Trust Co's holdings in 10x Genomics were worth $500,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in TXG. Wealth Enhancement Advisory Services LLC increased its stake in 10x Genomics by 9.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company's stock valued at $271,000 after purchasing an additional 2,564 shares in the last quarter. SG Americas Securities LLC increased its position in shares of 10x Genomics by 12.8% in the first quarter. SG Americas Securities LLC now owns 82,406 shares of the company's stock valued at $719,000 after buying an additional 9,360 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after buying an additional 1,614 shares during the last quarter. Pallas Capital Advisors LLC purchased a new stake in shares of 10x Genomics in the 1st quarter worth about $208,000. Finally, Rhumbline Advisers increased its holdings in 10x Genomics by 11.4% during the 1st quarter. Rhumbline Advisers now owns 120,490 shares of the company's stock valued at $1,052,000 after acquiring an additional 12,374 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TXG. The Goldman Sachs Group dropped their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a research note on Monday, May 12th. Citigroup cut their price target on 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research report on Friday. Bank of America increased their price objective on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. Finally, UBS Group cut their target price on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, 10x Genomics currently has an average rating of "Hold" and a consensus target price of $14.96.

Insider Transactions at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,485 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $62,125.50. Following the transaction, the insider owned 448,374 shares in the company, valued at approximately $3,721,504.20. This trade represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Taich sold 4,044 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total transaction of $33,565.20. Following the sale, the chief financial officer owned 331,588 shares of the company's stock, valued at approximately $2,752,180.40. This represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,872 shares of company stock worth $173,238. 10.03% of the stock is currently owned by company insiders.

10x Genomics Trading Up 4.1%

Shares of TXG traded up $0.48 during mid-day trading on Tuesday, reaching $12.06. The company had a trading volume of 3,510,369 shares, compared to its average volume of 3,487,722. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $24.76. The firm has a fifty day simple moving average of $9.45 and a 200-day simple moving average of $11.15. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -9.28 and a beta of 1.99.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative return on equity of 23.22% and a negative net margin of 25.14%. The business had revenue of $154.88 million for the quarter, compared to analyst estimates of $131.91 million. During the same period last year, the company posted ($0.50) EPS. The business's quarterly revenue was down 2.3% on a year-over-year basis. As a group, equities analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.